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Malignant melanoma is a life-threatening skin cancer due to its highly metastatic character and resistance to radio- and chemotherapy.
It is believed that the ability to evade apoptosis is the key mechanism for the rapid growth of cancer cells. However, the exact
mechanism for failure in the apoptotic pathway in melanoma cells is unclear. p53, the most frequently mutated tumour suppressor
gene in human cancers, is a key apoptosis inducer. However, p53 mutation is only found in 15–20% of melanoma biopsies. Recently,
it was found that Apaf-1, a downstream target of p53, is inactivated in metastatic melanoma. Specifically, loss of heterozygosity (LOH)
of the Apaf-1 gene was found in 40% of metastatic melanoma. To determine if loss of Apaf-1 expression is indeed involved in
melanoma progression, we employed the tissue microarray technology and examined Apaf-1 expression in 70 human primary
malignant melanoma biopsies by immunohistochemistry. Our data showed that Apaf-1 expression is significantly reduced in
melanoma cells compared with normal nevi (w
2¼6.02, P¼0.014). Our results also revealed that loss of Apaf-1 was not associated
with the tumour thickness, ulceration or subtype, patient’s gender, age and 5-year survival. In addition, our in vitro apoptosis assay
revealed that overexpression of Apaf-1 can sensitise melanoma cells to anticancer drug treatment. Taken together, our data indicate
that Apaf-1 expression is significantly reduced in human melanoma and that Apaf-1 may serve as a therapeutic target in melanoma.
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Cutaneous malignant melanoma is a deadly skin cancer, which is
derived from epidermal melanocytes. The incidence of melanoma
is increasing more rapidly than any other tumours among
Caucasian populations (Rigel et al, 1996). It is estimated that the
lifetime risk for melanoma has increased by 15-fold in the past 60
years, reaching one in 68 in America (Glass and Hoover, 1989; Koh
and Geller, 1995; Jemal et al, 2002, Rigel, 2002). Although early
melanomas are curable with surgical excision (Balch et al, 2001),
up to 20% of patients will develop metastatic tumours due to its
high capability of invasion and rapid metastasis to other organs
(Houghton and Polsky, 2002). Patients with metastatic melanoma
have a poor prognosis, with a median survival of only 6–10
months (Jemal et al, 2002).
The main obstacle in treating melanoma is its resistant
characteristic to conventional chemotherapy, with an overall
response rate of only less than 20% (Gilchrest et al, 1999; Li and
McClay, 2002). Although the molecular mechanism for drug
resistance in melanoma is still poorly understood, it appears that
the low therapeutic efficacy in this disease likely relates to a
relative inability to induce apoptosis (Li et al, 1998; Soengas and
Lowe, 2003). In addition, resistance to apoptosis has been
correlated with increased metastatic potential in melanoma
(Glinsky et al, 1997). p53, a central sensor linking DNA damage
to apoptosis, has been related to tumorigenesis and chemoresis-
tance in many tumour types (Fridman and Lowe, 2003; Oren,
2003), including melanoma (Li et al, 2000). However, melanomas
display a very low rate of p53 mutations (Albino et al, 1994;
Montano et al, 1994; Ragnarsson-Olding et al, 2002) despite their
extreme chemoresistance. Thus, dysregulation of other compo-
nents of the p53-mediated pathway in melanoma may also
contribute to disruption of apoptosis. In fact, altered expression
of downstream effectors of p53 such as IAP family members
(Grossman et al, 1999) and Bcl-2 family members (Bush and Li,
2003; Hakansson et al, 2003) have been reported in melanoma.
Recently, Apaf-1 gene, a downstream effector of p53, which links
release of cytochrome c to activation of caspase-9 in mitochon-
drion-mediated apoptosis pathway (Li et al, 1997), was found to be
inactivated in melanoma presumably by methylation (Soengas et al,
2001). Specifically, LOH of Apaf-1 alleles was detected in 42% of
the metastatic melanoma specimens and more than 50% of cell
lines that derived from metastatic melanoma showed negative
Apaf-1 expression. Strikingly, restoring physiological levels of
Apaf-1 through gene transfer or treatment with methylation
inhibitor can dramatically enhances chemosensitivity in Apaf-1-
deficient cell lines (Soengas et al, 2001), which raises the possibility
that restoring Apaf-1 regulation to some melanomas would have
therapeutic benefit.
To further investigate the role of Apaf-1 in melanoma
progression, we, used tissue microarray (TMA) technology and
immunohistochemistry in the present study, to evaluate the Apaf-1
expression level in primary human melanoma at different stages.
Our data showed that Apaf-1 expression is significantly reduced in
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However, reduced Apaf-1 expression is not correlated with
melanoma thickness or 5-year patient survival. Also, our in vitro
cell survival and apoptosis assays demonstrated that overexpres-
sion of Apaf-1 in melanoma cells enhanced anticancer drug-
induced apoptosis, suggesting that Apaf-1 may serve as a
therapeutic target in melanoma.
MATERIAL AND METHODS
TMA construction
Formalin-fixed, paraffin-embedded tissues from 87 human pri-
mary melanomas and 16 nevi were used for our present study. All
specimens were obtained from the 1990 to 1997 archives of the
Department of Pathology, Vancouver General Hospital. The most
representative tumour area was carefully selected and marked on
the H&E-stained slide. The TMAs were assembled using a tissue-
array instrument (Beecher Instruments, Silver Spring, MD, USA)
consisting of thin-walled stainless steel punches and stylets used to
empty and transfer the needle content. The assembly was held in
an X–Y position guide equipped with semiautomatic micrometers,
with a 1-mm increment between individual samples and 3-mm
punch depth stop device. Briefly, the instrument was used to create
holes in a recipient block with defined array cores. A solid stylet,
which closely fits the needle, was used to transfer the tissue cores
into the recipient block. Taking into account the limitations of the
representative areas of the tumour, we used duplicate or triplicate
0.6-mm diameter tissue cores from each donor block. Multiple 4-
mm sections were cut with a Leica microtome. Sections were
transferred to adhesive-coated slides using routine histology
procedures. One section was routinely deparaffinised with
standard xylene and hydrated through graded ethanol in water,
then stained with H&E and covered with a coverslip. The
remaining sections were stored at room temperature for im-
munohistochemistry staining.
Immunohistochemistry of TMA
The TMA slides were dewaxed by heating at 551C for 30min and
by three washes, 5min each, with xylene. Tissues were rehydrated
by a series of 5-min washes in 100, 90 and 70% ethanol and
phosphate-buffered saline (PBS). Antigen retrieval was performed
by microwaving the samples for 4min, 20s at full power in 250ml
of 10mM sodium citrate (pH 6.0). Endogenous peroxidase activity
was blocked with 0.3% hydrogen peroxide for 20min. Nonspecific
binding was blocked with goat serum for 30min. The primary
polyclonal rabbit anti-Apaf-1 antibody (BD Biosciences, Missis-
sauga, Ontario, Canada) was diluted 1:300 using goat serum and
incubated at room temperature for 1h. After three washes, 2min
each with PBS, the sections were incubated with a biotinylated goat
anti-rabbit secondary antibody for 30min (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA). After three washes, 2min each with
PBS, horseradish peroxidase-streptavidin (Santa Cruz Biotechnol-
ogy) was added to the section for 30min, followed by another three
washes, 2min each with PBS. The samples were developed with
3,30-diaminobenzidine substrate (Vector Laboratories, Burlington,
Ontario, Canada) for 7min and counterstained with haematoxylin.
Then, the slides were dehydrated following a standard procedure
and sealed with coverslips. Negative controls were performed by
omitting Apaf-1 antibody during the primary antibody incubation.
Evaluation of immunostaining
The Apaf-1 staining in TMA was examined blinded by three
independent observers (including one dermatopathologist) simul-
taneously, and a consensus score was reached for each core. Due to
loss of biopsy cores, 70 cases of primary melanoma and 13 cases of
nevi could be evaluated for Apaf-1 staining. The staining intensity
was scored as negative (0), weak staining (1þ), moderate staining
(2þ) and strong staining (3þ). There was a high level of
consistency of immunohistochemical staining between the dupli-
cate or triplicate cores in the TMAs. In total, 78% of the biopsies
had uniform staining between different cores. For the other 22% of
cases that had one level of difference in staining between cores, the
higher score was used for statistical analysis. The reason for
differential staining in some biopsies could be that melanoma is a
heterogeneous tumour, so different areas in the tumour may
represent different stages of tumour progression.
Statistical analysis of TMA
Statistical analysis was performed with the SPSS 11.5 software
(SPSS, Chicago, IL, USA). The w
2-test was used to compare the
quantitative differences of Apaf-1 expression in tumours and nevi.
The association between the Apaf-1 expression and the clinico-
pathological parameters, including age, sex, tumour thickness,
location, histological subtype and tumour ulceration, was also
evaluated by w
2 test. The relationship between Apaf-1 expression
and 5-year survival was assessed by log-rank test. A P-value of
o0.05 was considered significant.
Cell culture and transfection
Melanoma cell lines MMRU (p53
WT) and MEWO (p53
MUT) were
grown at 371C in Dulbecco’s modified Eagle’s medium containing
10% fetal bovine serum in an atmosphere containing 5% CO2. For
transfection, cells were grown to 50–60% confluency. The ratio of
1mg DNA:25ml Effectene reagent (Qiagen, Mississauga, Ontario,
Canada) was used for transfection. Plasmids used for transfection
included pEGFP-N1 control plasmid (BD Clontech, Palo Alto, CA,
USA) and pcDNA3-Apaf-1 (a kind gift from Dr K Bhalla, H Lee
Moffitt Cancer Centre, Tampa, FL, USA).
Western blot analysis
Cells were washed with PBS three times, and lysed in triple-
detergent buffer (50mM Tris-Cl (pH 8.0), 150mM NaCl, 0.02%
sodium azide, 0.1% SDS, 100mgml
 1 phenylmethylsulphonyl
fluoride, 1mgml
 1 aprotinin, 1% Nonidet P-40, 0.5% sodium
deoxycholate) for 20min on ice. The lysate was centrifuged at
12000g for 10min and the supernatant was collected. The protein
concentration was determined by the DC Protein Assay (Bio-Rad,
Mississauga, Ontario, Canada). In total, 50mglane
 1 of proteins
were separated on 6.5% polyacrylamide/SDS gels and electro-
blotted onto polyvinylidene difluoride filters. The filters were then
blocked with 5% skimmed milk for 1h and incubated with 1:1000
polyclonal rabbit anti-Apaf-1 antibody (BD Biosciences, Missis-
sauga, Ontario, Canada) for 1h at room temperature, and then
incubated with horseradish peroxidase-conjugated secondary
antibody for 1h at room temperature. The signals were detected
with SuperSignal enhanced chemiluminescence (Pierce, Rockford,
IL, USA).
Cell survival assay
MMRU cells were grown to 50–60% confluency in 24-well plates
and transfected with pEGFP-N1 or pcDNA3-Apaf-1 plasmid. At
24h after transfection, the cells were treated with 500nM
doxorubicin (DOX), 800nM vincristine (VIN) or 200nM camp-
tothecin (CPT) (Sigma, Mississauga, Ontario, Canada) for another
24h and the cell survival was determined by sulphorhodamine
(SRB) assay (Bush et al, 2001). Briefly, the medium was removed
and the cells were fixed with 10% trichloroacetate for 1h at 41C,
rinsed five times with water, and air-dried. The cells were then
fixed with 0.4% suphforhodamine B (SRB) in 1% acetic acid for
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500mlo f1 0m M Tris (pH 10.5) was added to the wells for 30min.
The colorimetric reading was carried out in a Microplate
Autoreader (Bio-Tek Instruments Inc., Winooski, VT, USA) at
550nm.
Enzyme-linked immunosorbent assay (ELISA) of apoptosis
MMRU and MEWO cells were grown to 50–60% confluency in 24-
well plates and transfected with pEGFP-N1 or pcDNA3-Apaf-1
plasmid. At 24h after transfection, the cells were treated with or
without 200nM CPT for 24h. The ELISA was then performed using
a Cell Death Detection Elisa
plus kit (Boehringer Mannheim,
Quebec, Canada) according to the manufacturer’s protocol. The
colorimetric analysis was carried out in a Microplate Autoreader
(Bio-Tek Instruments Inc., Winooski, VT, USA) at 405nm.
RESULTS
Clinicopathological features of TMA
For the 70 primary melanoma cases in which Apaf-1 staining was
available, there were 38 male and 32 female, with ages ranging
from 21 to 93 years (mean¼58). For melanoma staging, we used
Breslow thickness as our criteria for evaluating Apaf-1 expression:
p0.75mm, low risk; 0.76–1.5mm, intermediate risk; 1.51–
4.0mm, high risk; 44.0mm, very high risk (Marghoob et al,
2000). In our study, 14 melanoma cases were p0.75mm, 39 were
0.76–1.5mm, 11 were 1.51–4.0mm, and six were 44.0mm thick.
Among the 70 cases, 32 were superficial spreading melanoma, 12
were lentigo maligna melanoma, and other 26 cases consisted of
desmoplastic melanoma, acrolentigous melanoma, and nodular
melanoma. In total, 14 melanomas were located in sun-exposed
sites (head and neck), and 56 were located in sun-protected sites
(trunk, arm, leg, and feet). Tumour ulceration was observed in
nine cases (Table 1).
Apaf-1 expression in human melanoma
We examined Apaf-1 expression in primary melanomas and nevi
by immunohistochemistry. Various levels of Apaf-1 expression
were observed in the cytoplasm of the biopsies (Figure 1). Among
the 70 melanoma primaries, six cases (8.6%) showed negative (0),
36 cases (51.4%) weak (1þ), 21 cases (30%) moderate (2þ), and
seven cases (10%) strong (3þ) Apaf-1 staining. In contrast to
melanoma primaries, majority (76.9%) of the nevi had moderate or
strong Apaf-1 expression (eight and two cases, respectively), while
only one case stained negative and two cases showed weak Apaf-1
staining (Figure 2). A significant difference in the staining pattern
between tumours and nevi was observed (w
2¼6.02, P¼0.014).
Apaf-1 expression and clinicopathological parameters or 5-
year survival
To assess whether reduced Apaf-1 expression is associated with
melanoma progression, we examined Apaf-1 expression in 70
melanoma primaries at various stages of invasion. As shown in
Table 1, tumours with negative or weak Apaf-1 expression were
distributed fairly evenly among the various Breslow thickness
categories (P40.05, w
2 test). Tumour ulceration is often con-
sidered an indicator for melanoma prognosis (Vihinen et al, 2003),
but in our study, we did not find any correlation between Apaf-1
expression and tumour ulceration status (P40.05, w
2 test). In
addition, we did not find correlation between Apaf-1 expression
with age, sex, tumour subtype, or location of tumours (sun
protected vs sun exposed) (Table 1). To evaluate whether Apaf-1
staining might be related to patient survival, a Kaplin–Meier
survival curve was constructed using overall 5-year survival to
Table 1 Apaf-1 expression and clinicopathological characteristics of 70 primary melanomas
Intensity of Apaf-1 staining
0 1+ 2+ 3+ Total P-value
a
Age
p57 3 (8%) 20 (56%) 9 (25%) 4 (11%) 36
457 3 (9%) 16 (47%) 12 (35%) 3 (9%) 34 P40.05
Sex
Male 2 (5%) 18 (47%) 12 (32%) 6 (16%) 38
Female 4 (13%) 18 (56%) 9 (28%) 1 (3%) 32 P40.05
Tumour thickness (mm)
p0.75 2 (14%) 6 (43%) 4 (29%) 2 (14%) 14
0.76–1.5 4 (10%) 20 (51%) 10 (26%) 5 (13%) 39
1.51–4.0 0 (0%) 7 (64%) 4 (36%) 0 (0%) 11
44.0 0 (0%) 3 (50%) 3 (50%) 0 (0%) 6 P40.05
b
Ulceration
Absent 6 (10%) 30 (49%) 18 (30%) 7 (11%) 61
Present 0 (0%) 6 (67%) 3 (33%) 0 (0%) 9 P40.05
Tumour subtype
c
SSM 4 (13%) 13 (41%) 12 (38%) 3 (9%) 32
LMM 2 (17%) 5 (42%) 4 (33%) 1 (8%) 12
Other 0 (0%) 18 (69%) 5 (19%) 3 (12%) 26 P40.05
Site
d
Sun-protected 4 (7%) 28 (50%) 18 (32%) 6 (11%) 56
Sun-exposed 2 (14%) 8 (57%) 3 (21%) 1 (7%) 14 P40.05
aw
2 test for low (0, 1+) vs high Apaf-1 expression (2+, 3+).
bTumours p1.5mm vs 41.5mm.
cSSM¼superficial spreading melanoma; LMM¼lentigo maligna melanoma; Other
includes desmoplastic melanoma, acrolentigous melanoma and nodular melanoma.
dSun-protected sites: trunk, arm, leg and feet. Sun-exposed sites: head and neck.
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stained moderate or strong (2þ,3 þ) for Apaf-1 expression
(Figure 3). Our data did not show a correlation between Apaf-1
staining and 5-year patients survival (P40.05, log-rank test).
Overexpression of Apaf-1 enhances chemosensitivity in
melanoma cells
To investigate if Apaf-1 can increase the chemosensitivity in
melanoma cells, MMRU cells were overexpressed with Apaf-1 by
transient transfection (Figure 4A), followed by various anticancer
drug treatments. Cell survival assay revealed that overexpression
of Apaf-1 reduced cell survival to 63, 62 and 43% after treatment
with doxorubicin, vincristine or camptothecin, respectively,
compared with drug treatment alone (88, 83 and 66%)
(Figure 4B). Our data showed that camptothecin (CPT) was the
most effective drug at reducing cell survival with the concentra-
tions used for the experiment. To further determine the extent of
apoptosis, we then used an ELISA-based protocol, which quantifies
the number of histone/DNA particles that are cleaved during the
apoptotic process. As shown in Figure 4C, overexpression of Apaf-
1 in MMRU cells increased apoptosis by 25-fold over the GFP-
transfected control cells while this value was more than doubled
(64-fold) after 200nM CPT treatment. Furthermore, in a mutant-
p53 MEWO cell line, overexpression of Apaf-1 induced 14- and 26-
fold apoptosis in control and 200nM CPT-treated cells, respectively
(Figure 4C). These results indicate that Apaf-1 can sensitise
melanoma cells to chemotherapy.
DISCUSSION
Acquired resistance to apoptosis is a hallmark of cancers
(Hanahan and Weinberg, 2000), which can allow cancer cells to
Figure 1 Apaf-1 expression in human melanoma tissue microarray. (A)
Adjacent normal epidermis with strong Apaf-1 expression (3þ). (B)
Normal nevus with moderate Apaf-1 expression (2þ). (C) Melanoma
with weak Apaf-1 expression (1þ). Magnification,  400.
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Figure 2 Apaf-1 expression in normal nevi and melanoma. There is
significantly less Apaf-1 expression in tumour tissues compared to normal
nevi (P¼0.014, w
2 test).
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Figure 3 Correlation between Apaf-1 expression and 5-year patient
survival. Apaf-1 expression is not correlated to 5-year patient survival
(P40.05, log-rank test).
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ysurvive and enable the establishment of metastasis or resistance to
chemotherapy. Malignant melanoma is a particularly aggressive
form of cancer in this regard. It is both highly metastatic and
resistant to chemotherapy. Many chemotherapeutic agents, such as
taxanes, vinca alkaloids and platinum-associated drugs, have failed
to introduce a significant response in melanomas. Even DTIC, the
only FDA-approved drug for the treatment of malignant melanoma
can only cure 5–10% of patients (Soengas and Lowe, 2003).
Defects in the apoptotic pathways can be the cause of tumour
progression and resistance to chemotherapy. Inactivation of Apaf-
1, a key effector of the intrinsic apoptosis pathway, and its effect on
chemotherapy have been observed in several tumour types,
including gastrointestinal cancer, leukemia, ovarian cancer and
melanoma (Yamamoto et al, 2000; Jia et al, 2001; Soengas et al,
2001; Wolf et al, 2001; Liu et al, 2002). In this study, to better
understand the role of Apaf-1 in melanoma development, we used
TMA technology and immunohistochemistry to investigate Apaf-1
expression level in primary human melanoma biopsies. Our results
demonstrated that Apaf-1 expression is significantly reduced in
melanoma compared to normal nevi (P¼0.014) (Figure 2).
However, despite the Apaf-1 reduction in melanoma, our data
showed that Apaf-1 expression is not related to melanoma
thickness (Table 1) or 5-year patient survival (Figure 3), suggesting
that Apaf-1 reduction is an early event of melanoma tumorigen-
esis, possibly at the initiation stage.
The reduction of Apaf-1 expression in melanoma biopsies
observed in our study is in agreement with previous studies
demonstrating inactivation of Apaf-1 in melanoma cell lines
(Soengas et al, 2001). The reversion of Apaf-1 expression by the
methylation inhibitor 5-aza-20-deoxycytidine in melanoma cells
(Soengas et al, 2001) suggests that hypermethylation of Apaf-1
promoter or the upstream regulators may contribute to the
reduction/loss of Apaf-1 expression in melanoma. Normal expres-
sion of Apaf-1 is an important component in the p53/mitochon-
drial intrinsic apoptosis pathway. Proapoptotic signal from p53
can result in the release of cytochrome c from the mitochondria. In
the presence of cytochrome c and dATP, Apaf-1 binds to
procaspase-9, leading to caspase-9 activation and initiation of a
protease cascade (Li et al, 1997). Thus, reduced Apaf-1 expression
in melanoma may terminate the apoptotic signal from mitochon-
dria, thus disabling the p53 apoptotic program.
Our data that Apaf-1 reduction did not correlate with tumour
thickness is in agreement with the findings by Fujimoto et al
(2004), who showed that the pattern of Apaf-1 LOH did not
correlate with tumour Breslow thickness, while Apaf-1 mRNA
expression level was significantly lower in Apaf-1 LOH positive
tumours. Contrarily, Baldi et al (2004) reported that reduced Apaf-
1 expression correlated with melanoma thickness. The following
reasons may result in the discrepancy between our results and
those by Baldi et al: (1) different antibodies used for immunohis-
tochemical staining; and (2) different technical approaches for
immunohistochemisty. We used TMA technique for our study and
all the nevi and tumour biopsies were assembled in one slide.
Therefore, all the samples had exactly the same treatment for each
step during immunohistochemical staining. On the other hand,
Baldi et al used regular immunohistochemistry for their study, so
there may exist inconsistency between different slides during the
staining procedure for 106 biopsies. Future TMA studies of
additional tumour biopsies will validate the role of Apaf-1 in
melanoma progression.
Our finding that no significant correlation between reduced
Apaf-1 expression and tumour thickness favours a multiple-event
model that a number of important molecular changes occur
sequentially during melanoma progression. Dysfunction of other
components in the apoptotic pathway as well as the survival
pathway may contribute to melanoma progression. For example,
survivin, a member of the inhibitor of apoptosis protein (IAP)
family, was strongly expressed in human melanomas but not in
normal melanocytes, and overexpression of survivin in the sentinel
lymph nodes from melanoma patients was inversely correlated
with patient survival (Grossman et al, 1999; Gradilone et al, 2003).
High expression of Bcl-2 antiapoptotic proteins, such as Bcl-2, Bcl-
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Figure 4 Overexpression of Apaf-1 sensitises melanoma cells to
anticancer drug treatment. (A) Western blot showing endogenous level
of Apaf-1 parental MMRU and MMRU cells transfected with Apaf-1. (B)
Decreased cell survival of melanoma cells overexpressing Apaf-1. MMRU
cells were either transfected with control GFP or Apaf-1 cDNAs followed
by various drug treatment: DOX (500nM), VIN (800nM), or CPT (200nM)
for 24h, and the cell survival rate was determined by SRB assay. (C)
Increased apoptosis of melanoma cells overexpressing Apaf-1. MMRU and
MEWO cells were transfected with GFP or Apaf-1, and then treated with
200nM CPT for 24h followed by ELISA assay of apoptosis.
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yXL, and Mcl-1, may also contribute to melanoma progression and
chemoresistance as antisense oligos against these genes can induce
death of melanoma cells (Jansen et al, 1998; Heere-Ress et al, 2002;
Thallinger et al, 2003). However, the implication of Bcl-2
antiapoptotic proteins as melanoma progression factors is
controversial. While some studies indicated that Bcl-2 and Bcl-
XL gene expression increases with progression of malignant
melanoma (Leiter et al, 2000; Utikal et al, 2002), others found
that Bcl-2 and Bcl-XL did not correlate to progression of the
disease (Gradilone et al, 2003). In the PI3K/AKT/PTEN survival
pathway, AKT has been found to be constitutively activated in
melanoma, which leads to upregulation of NFkB and tumour
progression (Dhawan et al, 2002). Recently, we demonstrated that
the integrin linked kinase (ILK), a direct regulator of AKT activity,
is overexpressed in melanoma and increased ILK expression is
correlated with melanoma thickness and 5-year patient survival
(Dai et al, 2003). As the negative regulator of this pathway, PTEN
expression was found to be reduced in melanoma biopsies and loss
of PTEN can promote tumour growth in vivo (Stahl et al, 2003;
Tsao et al, 2003). Based on the complexity of the apoptotic and
survival pathways that control the fate of a cell, additional studies
on the timing of the gene inactivation/overexpression in these
pathways from the same set of tumour biopsies and the
interdependence among these events will provide a more complete
picture of the molecular changes during melanoma initiation and
progression. Given the fact that many factors participate in the
governance of the fate of melanoma cells, it is worth targeting
multiple molecules in different pathways as a therapeutic
approach.
Our data that reduced Apaf-1 expression did not correlate with
5-year survival of patients with primary melanoma is consistent
with the findings by Fujimoto et al (2004), who showed that Apaf-1
LOH correlated with poorer prognosis of metastatic, but not
primary melanoma patients. These data also suggest that the
involvement of Apaf-1 in melanoma tumorigenesis is very
complex. Loss of Apaf-1 may trigger the initiation of malignant
transformation of melanocytes. However, additional genetic
changes are required for the vertical growth phase progression
of melanoma. Nevertheless, overexpression of Apaf-1 in melanoma
cells sensitised melanoma cells to anticancer drug treatment
(Figure 4), suggesting that loss of Apaf-1 expression may cause
chemoresistance in melanoma. Since the Apaf-1 expression is
significantly reduced in melanomas and overexpression of Apaf-1
enhances anticancer drug-induced apoptosis, reversion of the
reduced Apaf-1 expression should be considered in the design of
novel strategies for the treatment of melanoma patients.
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